Bayesian graphical modeling for heterogeneous causal effects

TL;DR

This paper introduces a Bayesian graphical modeling approach using Dirichlet Process mixtures to estimate heterogeneous causal effects in personalized medicine, specifically applied to AML treatment data.

Contribution

It develops a novel Bayesian DAG model that accounts for individual heterogeneity through clustering, enabling personalized causal effect estimation.

Findings

Identified different protein regulation effects among patients.

Clustered patients into groups with novel classifications.

Provided subject-specific causal effect estimates.

Abstract

Our motivation stems from current medical research aiming at personalized treatment using a molecular-based approach. The broad goal is to develop a more precise and targeted decision making process, relative to traditional treatments based primarily on clinical diagnoses. Specifically, we consider patients affected by Acute Myeloid Leukemia (AML), an hematological cancer characterized by uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Because AML responds poorly to chemoterapeutic treatments, the development of targeted therapies is essential to improve patients' prospects. In particular, the dataset we analyze contains the levels of proteins involved in cell cycle regulation and linked to the progression of the disease. We analyse treatment effects within a causal framework represented by a Directed Acyclic Graph (DAG) model, whose vertices are the protein levels in the network. A major obstacle in implementing the above program is however represented by individual heterogeneity. We address this issue through a Dirichlet Process (DP) mixture of Gaussian DAG-models where both the graphical structure as well as the allied model parameters are regarded as uncertain. Our procedure determines a clustering structure of the units reflecting the underlying heterogeneity, and produces subject-specific estimates of causal effects based on Bayesian model averaging. With reference to the AML dataset, we identify different effects of protein regulation among individuals; moreover, our method clusters patients into groups that exhibit only mild similarities with traditional categories based on morphological features.